远端胰腺切除术后新发糖尿病的发病机制与临床管理

阿拉帕提·外力; 韩玮

doi:10.12449/JCH250738

远端胰腺切除术后新发糖尿病的发病机制与临床管理

DOI: 10.12449/JCH250738

阿拉帕提·外力,
韩玮^, ,

新疆医科大学第一附属医院胰腺外科，乌鲁木齐 830000

基金项目:

国家自然科学基金 (82360585)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：阿拉帕提·外力负责课题设计，资料分析，撰写论文及修改论文；韩玮负责拟定写作思路，指导撰写文章，提供基金支持并最后定稿。

详细信息

通信作者:
韩玮， 13999846637@139.com （ORCID： 0009-0008-8918-0525）

计量
- 文章访问数: 405
- HTML全文浏览量: 168
- PDF下载量: 23
- 被引次数: 0
出版历程
- 收稿日期: 2024-11-10
- 录用日期: 2024-12-11
- 出版日期: 2025-07-25

Pathogenesis and clinical management of new-onset diabetes mellitus after distal pancreatectomy

Waili ALAPATI,
Wei HAN^{,
,}

Department of Pancreatic Surgery，The First Affiliated Hospital of Xinjiang Medical University，Urumqi 830000，China

Research funding:

National Natural Science Foundation of China (82360585)

More Information

Corresponding author: HAN Wei， 13999846637@139.com （ORCID： 0009-0008-8918-0525）

摘要

摘要: 胰源性糖尿病是一种继发于胰腺疾病的特殊类型糖尿病。胰腺切除术是导致胰源性糖尿病的主要病因之一，其中以远端胰腺切除术后发病率最高。由于胰源性糖尿病临床误诊率高，且患者较2型糖尿病患者具有更高的死亡和再入院风险，早期准确识别和诊断对改善预后至关重要。本文系统综述了远端胰腺切除术后新发糖尿病的流行病学特征、危险因素、病理生理机制、诊断标准和治疗策略的研究进展，为临床诊疗和科学研究提供参考。
- 胰腺切除术 /
- 糖尿病 /
- 危险因素 /
- 诊断 /
- 治疗学
Abstract: Pancreatogenic diabetes is a special form of diabetes secondary to pancreatic diseases. Pancreatectomy is one of the main causes of pancreatogenic diabetes， with the highest incidence rate observed after distal pancreatectomy. Due to the high misdiagnosis rate of pancreatogenic diabetes and the increased risk of death and readmission in patients with pancreatogenic diabetes compared with those with type 2 diabetes， early accurate identification and diagnosis of pancreatogenic diabetes are of great importance for improving prognosis. This article systematically reviews the research advances in new-onset diabetes after distal pancreatectomy in terms of epidemiological features， risk factors， pathophysiological mechanism， diagnostic criteria， and treatment strategies， in order to provide a reference for clinical diagnosis， treatment， and scientific research.
- Pancreatectomy /
- Diabetes Mellitus /
- Risk Factors /
- Diagnosis /
- Therapeutics

HTML全文

图 1 DP术后NODM的发病机制示意图

Figure 1. Schematic diagram of the pathogenesis of NODM after DP

下载: 全尺寸图片幻灯片

表 1 近5年相关报道中的DP术后NODM发病率

Table 1. Incidence of NODM after DP in articles published in the last 5 years

第一作者	发表年份（年）	随访时间（月）	发病率	文献
Imamura S	2024	36.0	74.1%	［8］
Chen ZH	2023	42.8	29.1%	［9］
Firkins SA	2022	24.0	20.2%	［10］
Sera N	2021	48.0	28.9%	［11］
Tariq M	2020	24.0	36.0%	［12］
Maxwell DW	2020	120.0	42.9%	［13］

下载: 导出CSV

参考文献(52)

[1]	American Diabetes Association Professional Practice Committee. 2. classification and diagnosis of diabetes: Standards of medical care in diabetes-2022[J]. Diabetes Care, 2022, 45( Suppl 1): S17- S38. DOI: 10.2337/dc22-S002.
[2]	SUN H, SAEEDI P, KARURANGA S, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183: 109119. DOI: 10.1016/j.diabres.2021.109119.
[3]	HARDT PD, BRENDEL MD, KLOER HU, et al. Is pancreatic diabetes(type 3c diabetes) underdiagnosed and misdiagnosed?[J]. Diabetes Care, 2008, 31( Suppl 2): S165- S169. DOI: 10.2337/dc08-s244.
[4]	WEI JL, OU YR, CHEN JT, et al. Mapping global new-onset, worsening, and resolution of diabetes following partial pancreatectomy: A systematic review and meta-analysis[J]. Int J Surg, 2024, 110( 3): 1770- 1780. DOI: 10.1097/JS9.0000000000000998.
[5]	WANG XJ, MISAWA R, ZIELINSKI MC, et al. Regional differences in islet distribution in the human pancreas: Preferential beta-cell loss in the head region in patients with type 2 diabetes[J]. PLoS One, 2013, 8( 6): e67454. DOI: 10.1371/journal.pone.0067454.
[6]	SACHS T, PRATT WB, CALLERY MP, et al. The incidental asymptomatic pancreatic lesion: Nuisance or threat?[J]. J Gastrointest Surg, 2009, 13( 3): 405- 415. DOI: 10.1007/s11605-008-0788-0.
[7]	YU JW, SUN R, HAN XL, et al. New-onset diabetes mellitus after distal pancreatectomy: A systematic review and meta-analysis[J]. J Laparoendosc Adv Surg Tech A, 2020, 30( 11): 1215- 1222. DOI: 10.1089/lap.2020.0090.
[8]	IMAMURA S, NIWANO F, BABAYA N, et al. High incidence of diabetes mellitus after distal pancreatectomy and its predictors: A long-term follow-up study[J]. J Clin Endocrinol Metab, 2024, 109( 3): 619- 630. DOI: 10.1210/clinem/dgad634.
[9]	CHEN ZH, SHI N, XING C, et al. A novel clinical model for risk prediction and stratification of new-onset diabetes mellitus after distal pancreatectomy[J]. Hepatobiliary Surg Nutr, 2023, 12( 6): 868- 881. DOI: 10.21037/hbsn-22-382.
[10]	FIRKINS SA, HART PA, PORTER K, et al. Incidence and risk factors for new-onset diabetes mellitus after surgical resection of pancreatic cystic lesions: A MarketScan study[J]. Pancreas, 2022, 51( 5): 427- 434. DOI: 10.1097/MPA.0000000000002054.
[11]	SERA N, NAKAMURA T, HORIE I, et al. Characteristics of patients who developed glucose intolerance in the early period after partial pancreatectomy[J]. Diabetol Int, 2021, 12( 1): 140- 144. DOI: 10.1007/s13340-020-00440-y.
[12]	TARIQ M, JAJJA MR, MAXWELL DW, et al. Diabetes development after distal pancreatectomy: Results of a 10 year series[J]. HPB(Oxford), 2020, 22( 7): 1034- 1041. DOI: 10.1016/j.hpb.2019.10.2440.
[13]	MAXWELL DW, JAJJA MR, GALINDO RJ, et al. Post-pancreatectomy diabetes index: A validated score predicting diabetes development after major pancreatectomy[J]. J Am Coll Surg, 2020, 230( 4): 393- 402. e 3. DOI: 10.1016/j.jamcollsurg.2019.12.016.
[14]	SHIRAKAWA S, MATSUMOTO I, TOYAMA H, et al. Pancreatic volumetric assessment as a predictor of new-onset diabetes following distal pancreatectomy[J]. J Gastrointest Surg, 2012, 16( 12): 2212- 2219. DOI: 10.1007/s11605-012-2039-7.
[15]	DAI MH, XING C, SHI N, et al. Risk factors for new-onset diabetes mellitus after distal pancreatectomy[J]. BMJ Open Diab Res Care, 2020, 8( 2): e001778. DOI: 10.1136/bmjdrc-2020-001778.
[16]	YAMADA D, TAKAHASHI H, ASUKAI K, et al. Investigation of the influence of pancreatic surgery on new-onset and persistent diabetes mellitus[J]. Ann Gastroenterol Surg, 2021, 5( 4): 575- 584. DOI: 10.1002/ags3.12435.
[17]	NGUYEN A, DEMIRJIAN A, YAMAMOTO M, et al. Development of postoperative diabetes mellitus in patients undergoing distal pancreatectomy versus Whipple procedure[J]. Am Surg, 2017, 83( 10): 1050- 1053.
[18]	HAMAD A, HYER JM, THAYAPARAN V, et al. Pancreatogenic diabetes after partial pancreatectomy: A common and understudied cause of morbidity[J]. J Am Coll Surg, 2022, 235( 6): 838- 845. DOI: 10.1097/XCS.0000000000000360.
[19]	KANG JS, JANG JY, KANG MJ, et al. Endocrine function impairment after distal pancreatectomy: Incidence and related factors[J]. World J Surg, 2016, 40( 2): 440- 446. DOI: 10.1007/s00268-015-3228-9.
[20]	SHEN JL, CAO JS, HE J, et al. Clinical utility of resected pancreatic volume ratio calculation for predicting postoperative new-onset diabetes mellitus after distal pancreatectomy-a propensity-matched analysis[J]. Heliyon, 2023, 9( 5): e15998. DOI: 10.1016/j.heliyon.2023.e15998.
[21]	SHINGYOJI A, MIKATA R, OGASAWARA S, et al. Diverse transitions in diabetes status during the clinical course of patients with resectable pancreatic cancer[J]. Jpn J Clin Oncol, 2020, 50( 12): 1403- 1411. DOI: 10.1093/jjco/hyaa136.
[22]	NIWANO F, BABAYA N, HIROMINE Y, et al. Three-year observation of glucose metabolism after pancreaticoduodenectomy: A single-center prospective study in Japan[J]. J Clin Endocrinol Metab, 2022, 107( 12): 3362- 3369. DOI: 10.1210/clinem/dgac529.
[23]	MATVEYENKO AV, BUTLER PC. Relationship between beta-cell mass and diabetes onset[J]. Diabetes Obes Metab, 2008, 10 Suppl 4( 4): 23- 31. DOI: 10.1111/j.1463-1326.2008.00939.x.
[24]	de BRUIJN KM, van EIJCK CH. New-onset diabetes after distal pancreatectomy: A systematic review[J]. Ann Surg, 2015, 261( 5): 854- 861. DOI: 10.1097/sla.0000000000000819.
[25]	KING J, KAZANJIAN K, MATSUMOTO J, et al. Distal pancreatectomy: Incidence of postoperative diabetes[J]. J Gastrointest Surg, 2008, 12( 9): 1548- 1553. DOI: 10.1007/s11605-008-0560-5.
[26]	MAO YS, ZHAO XF, ZHOU LH, et al. Evaluating perioperative glycemic status after different types of pancreatic surgeries via continuous glucose monitoring system: A pilot study[J]. Gland Surg, 2021, 10( 10): 2945- 2955. DOI: 10.21037/gs-21-495.
[27]	KLOVER PJ, MOONEY RA. Hepatocytes: Critical for glucose homeostasis[J]. Int J Biochem Cell Biol, 2004, 36( 5): 753- 758. DOI: 10.1016/j.biocel.2003.10.002.
[28]	LEE BW, KANG HW, HEO JS, et al. Insulin secretory defect plays a major role in the development of diabetes in patients with distal pancreatectomy[J]. Metabolism, 2006, 55( 1): 135- 141. DOI: 10.1016/j.metabol.2005.08.005.
[29]	FUKUDA T, BOUCHI R, TAKEUCHI T, et al. Importance of intestinal environment and cellular plasticity of islets in the development of postpancreatectomy diabetes[J]. Diabetes Care, 2021, 44( 4): 1002- 1011. DOI: 10.2337/dc20-0864.
[30]	KIM-MULLER JY, FAN J, KIM YJR, et al. Aldehyde dehydrogenase 1a3 defines a subset of failing pancreatic β cells in diabetic mice[J]. Nat Commun, 2016, 7: 12631. DOI: 10.1038/ncomms12631.
[31]	SLEZAK LA, ANDERSEN DK. Pancreatic resection: Effects on glucose metabolism[J]. World J Surg, 2001, 25( 4): 452- 460. DOI: 10.1007/s002680020337.
[32]	AHRÉN B. Glucagon secretion in relation to insulin sensitivity in healthy subjects[J]. Diabetologia, 2006, 49( 1): 117- 122. DOI: 10.1007/s00125-005-0056-8.
[33]	HENKEL E, MENSCHIKOWSKI M, KOEHLER C, et al. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus[J]. Metabolism, 2005, 54( 9): 1168- 1173. DOI: 10.1016/j.metabol.2005.03.024.
[34]	SCHRADER H, MENGE BA, BREUER TGK, et al. Impaired glucose-induced glucagon suppression after partial pancreatectomy[J]. J Clin Endocrinol Metab, 2009, 94( 8): 2857- 2863. DOI: 10.1210/jc.2009-0826.
[35]	DINIĆ S, ARAMBAŠIĆ JOVANOVIĆ J, USKOKOVIĆ A, et al. Oxidative stress-mediated beta cell death and dysfunction as a target for diabetes management[J]. Front Endocrinol(Lausanne), 2022, 13: 1006376. DOI: 10.3389/fendo.2022.1006376.
[36]	LONYAI A, KODAMA S, BURGER D, et al. The promise of Hox11+ stem cells of the spleen for treating autoimmune diseases[J]. Horm Metab Res, 2008, 40( 2): 137- 146. DOI: 10.1055/s-2007-1022560.
[37]	DIEGUEZ-ACUNA FJ, GYGI SP, DAVIS M, et al. Splenectomy: A new treatment option for ALL tumors expressing Hox-11 and a means to test the stem cell hypothesis of cancer in humans[J]. Leukemia, 2007, 21( 10): 2192- 2194. DOI: 10.1038/sj.leu.2404927.
[38]	PARK S, HONG SM, AHN IS. Can splenocytes enhance pancreatic β-cell function and mass in 90% pancreatectomized rats fed a high fat diet?[J]. Life Sci, 2009, 84( 11-12): 358- 363. DOI: 10.1016/j.lfs.2008.12.022.
[39]	YOU L, YAO L, MAO YS, et al. Partial pancreatic tail preserving subtotal pancreatectomy for pancreatic cancer: Improving glycemic control and quality of life without compromising oncological outcomes[J]. World J Gastrointest Surg, 2020, 12( 12): 491- 506. DOI: 10.4240/wjgs.v12.i12.491.
[40]	ANDERSSON AK, FLODSTRÖM M, SANDLER S. Cytokine-induced inhibition of insulin release from mouse pancreatic beta-cells deficient in inducible nitric oxide synthase[J]. Biochem Biophys Res Commun, 2001, 281( 2): 396- 403. DOI: 10.1006/bbrc.2001.4361.
[41]	BÖNI-SCHNETZLER M, BOLLER S, DEBRAY S, et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I[J]. Endocrinology, 2009, 150( 12): 5218- 5229. DOI: 10.1210/en.2009-0543.
[42]	DONATH MY. Targeting inflammation in the treatment of type 2 diabetes: Time to start[J]. Nat Rev Drug Discov, 2014, 13( 6): 465- 476. DOI: 10.1038/nrd4275.
[43]	PONDUGALA PK, SASIKALA M, GUDURU VR, et al. Interferon-γ decreases nuclear localization of pdx-1 and triggers β-cell dysfunction in chronic pancreatitis[J]. J Interferon Cytokine Res, 2015, 35( 7): 523- 529. DOI: 10.1089/jir.2014.0082.
[44]	HUANG H, DONG X, KANG MX, et al. Novel blood biomarkers of pancreatic cancer-associated diabetes mellitus identified by peripheral blood-based gene expression profiles[J]. Am J Gastroenterol, 2010, 105( 7): 1661- 1669. DOI: 10.1038/ajg.2010.32.
[45]	EWALD N, BRETZEL RG. Diabetes mellitus secondary to pancreatic diseases(Type 3c): Are we neglecting an important disease?[J]. Eur J Intern Med, 2013, 24( 3): 203- 206. DOI: 10.1016/j.ejim.2012.12.017.
[46]	HART PA, BELLIN MD, ANDERSEN DK, et al. Type 3c(pancreatogenic) diabetes mellitus secondary to chronic pancreatitis and pancreatic cancer[J]. Lancet Gastroenterol Hepatol, 2016, 1( 3): 226- 237. DOI: 10.1016/S2468-1253(16)30106-6.
[47]	KANG MJ, JUNG HS, JANG JY, et al. Metabolic effect of pancreatoduodenectomy: Resolution of diabetes mellitus after surgery[J]. Pancreatology, 2016, 16( 2): 272- 277. DOI: 10.1016/j.pan.2016.01.006.
[48]	BELLIN MD. Pancreatogenic diabetes in children with recurrent acute and chronic pancreatitis: Risks, screening, and treatment(mini-review)[J]. Front Pediatr, 2022, 10: 884668. DOI: 10.3389/fped.2022.884668.
[49]	MAKUC J. Management of pancreatogenic diabetes: Challenges and solutions[J]. Diabetes Metab Syndr Obes, 2016, 9: 311- 315. DOI: 10.2147/DMSO.S99701.
[50]	LI DH, TANG HW, HASSAN MM, et al. Diabetes and risk of pancreatic cancer: A pooled analysis of three large case-control studies[J]. Cancer Causes Control, 2011, 22( 2): 189- 197. DOI: 10.1007/s10552-010-9686-3.
[51]	LÖHR JM, DOMINGUEZ-MUNOZ E, ROSENDAHL J, et al. United European Gastroenterology evidence-based guidelines for the diagnosis and therapy of chronic pancreatitis(HaPanEU)[J]. United European Gastroenterol J, 2017, 5( 2): 153- 199. DOI: 10.1177/2050640616684695.
[52]	CRAVALHO CKL, MEYERS AG, MABUNDO LS, et al. Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes[J]. Diabetologia, 2020, 63( 10): 2194- 2204. DOI: 10.1007/s00125-020-05236-y.